In Europe, the vaccine for the new coronavirus developed by British pharmaceutical giant AstraZeneca and others is lacking in efficacy data for the elderly aged 65 and over, and the elderly are urged to refrain from vaccination for the time being. Recommendations are coming one after another.
On the 29th of last month, EU-European Union officials said that the vaccine for the new coronavirus developed by AstraZeneca and Oxford University, which Japan has also signed a contract with, said that data over 55 years old was insufficient, but 18 We have issued permission to sell the product on condition that it is used by people over the age of.
In response to this, in the EU member states, each specialized agency has issued a recommendation on vaccination to the government, and in France on the 2nd, the top of the agency that evaluates medicines etc. held a press conference, "65 There is a lack of data on subjects over the age of 65. For the time being, we recommend using it under the age of 65. "
Efficacy data for the elderly will be available in the coming weeks and will be reassessed at that stage.
The French government is expected to refrain from vaccination of elderly people aged 65 and over in line with this recommendation.
In Sweden, a similar recommendation was issued on the 2nd, and the German government has indicated that it will refrain from vaccination of elderly people aged 65 and over following the recommendation of a committee by experts.
On the other hand, in the UK, AstraZeneca vaccination is also given to the elderly, and in Italy, the government's expert committee has concluded that the elderly should also be vaccinated.